Company news
BioVie Inc. news in 2026
BioVie Inc.'s news releases, calls and decks from 2026, newest first.
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
October 26, 2026
BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting
October 20, 2026
BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting
October 19, 2026
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
October 14, 2026
New to The Street Broadcasts Tonight at 6: 30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
September 19, 2026
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
September 15, 2026
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid
September 14, 2026
BioVie Announces Update to Parkinson's Phase 3 Development Program
September 9, 2026
BioVie Announces Update to Parkinson’s Phase 3 Development Program
September 8, 2026
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
August 31, 2026
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
August 6, 2026
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
May 27, 2026
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
May 26, 2026
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
April 27, 2026
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
April 13, 2026
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
March 11, 2026
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
February 22, 2026
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
February 12, 2026
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
January 8, 2026